CodeX effectively identifies high-risk patients with asthma or COPD in Dutch primary care, supporting guideline-driven treatment
Therapeutic Advances in Respiratory Disease · 2025
DOI: 10.1177/17534666251329192 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Therapeutic Advances in Respiratory Disease, 2025. Verfasst von Iris van Geer-Postmus und 13 weiteren Autor:innen. Beteiligte Einrichtung: General Practitioners Research Institute, Prof. ED Wiersmastraat 5, Groningen, 9713 GH, The Netherlands. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Asthma, Primary Health Care, Algorithms. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca the Netherlands.
Themen: COPD
Abstract (Originalsprache)
Background
Prevention of lung attacks (LAs)/exacerbation is an important treatment goal in both asthma and chronic obstructive pulmonary disease (COPD). However, LAs are often not registered as such in medical records.
Objectives
Development and evaluation of CodeX Asthma and COPD.
Design
An electronic medical record-based algorithm to identify LAs in Dutch primary care patients with asthma or COPD was developed. The algorithms were evaluated in nine general practices in the Netherlands.
Results
A total of 479 LAs (in 1164 patients) were identified with CodeX Asthma in the past year, of which only 16% were registered. CodeX COPD identified 321 LAs (in 242 patients) in the past 3 years, of which two were registered.
Conclusion
CodeX algorithms are capable of identifying unrecorded LAs and high-risk/uncontrolled patients in an easy way. This offers primary care providers a simple solution to easily identify and closely manage high-risk patients with asthma or COPD by identifying LAs’ frequency and potential under- or overtreatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- General Practitioners Research Institute, Prof. ED Wiersmastraat 5, Groningen, 9713 GH, The Netherlands.
- General Practitioners Research Institute, Groningen, The Netherlands.
- Department of Medical Informatics, Erasmus MC, Rotterdam, The Netherlands.
- Optimum Patient Care, Cambridge, United Kingdom of Great Britain and Northern Ireland.
- Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.
- Observational and Pragmatic Research Institute, Singapore, Singapore.
ORCID-Profile: Iris van Geer-Postmus, David Price
Förderung
- AstraZeneca the Netherlands
Zitieren
APA
van Geer-Postmus, I., Leving, M. T., Gerritsma, Y. H., Baan, E., Dijk, L., Harms, E., Price, D., Prins, G. H., Quint, J. K., Ryan, D., Salomé, P., Ställberg, B., Stoker, N., & Kocks, J. H. (2025). CodeX effectively identifies high-risk patients with asthma or COPD in Dutch primary care, supporting guideline-driven treatment. Therapeutic Advances in Respiratory Disease. https://doi.org/10.1177/17534666251329192
Vancouver
van Geer-Postmus I, Leving MT, Gerritsma YH, Baan E, Dijk L, Harms E, et al. CodeX effectively identifies high-risk patients with asthma or COPD in Dutch primary care, supporting guideline-driven treatment. Therapeutic Advances in Respiratory Disease. 2025. doi:10.1177/17534666251329192
BibTeX
@article{vanGeerPostmus2025,
author = {van Geer-Postmus, Iris and Leving, Marika T and Gerritsma, Yoran H and Baan, Esmé and Dijk, Lars and Harms, Evelien and Price, David and Prins, Gerian H and Quint, Jennifer K and Ryan, Dermot and Salomé, Philippe and Ställberg, Björn and Stoker, Nilouq and Kocks, Janwillem H},
title = {CodeX effectively identifies high-risk patients with asthma or COPD in Dutch primary care, supporting guideline-driven treatment},
journal = {Therapeutic Advances in Respiratory Disease},
year = {2025},
doi = {10.1177/17534666251329192}
}
EUVIMED